Double Your Innovation Impact at TIDES USA
Register for TIDES USA and add on exclusive access to the Obesity Science & Innovation Workshop
Two premier conferences, one powerful experience
A Snapshot of the Obesity Science & Innovation 2027 Agenda
GLP-1 & Next-Generation Multi-Agonist Therapies
Exploring clinical updates from leading GLP-1, dual, and triple agonist programs across peptide and small molecule modalities, including efficacy data and novel oral formulations addressing limitations of injectable therapies.
RNA-Based Approaches
Exploring RNA-based approaches for obesity, including siRNA-mediated inhibition of metabolic targets and non-coding RNA technologies with insights from Phase 1 clinical data.
Investment, Valuation & Strategic Partnerships
Examining valuation trends, licensing opportunities, and strategic collaborations shaping the obesity therapeutics landscape, with insights from leading investors, pharma BD&L teams, and emerging biotech innovators.
Digital Health Integration
Integrating digital health solutions with obesity therapeutics to enhance patient engagement, treatment adherence, and real-world outcomes through connected technologies and data-driven personalization.
Dedicated Networking Hours
Connect with pharmaceutical executives, biotech innovators, clinical researchers, and investors during structured networking breaks designed to foster collaboration, exchange insights, and build strategic partnerships across the obesity innovation ecosystem.
Why Attend Both TIDES USA and OSI?
The convergence of advanced therapeutic modalities and metabolic health innovation is reshaping drug development. From oligonucleotide-based RNA therapies to GLP-1 peptides, the technologies driving TIDES USA are directly enabling the obesity breakthroughs showcased at OSI.
The Modality-to-Application Connection
TIDES USA brings you the foundational science: oligonucleotide chemistry, peptide design, mRNA development, drug delivery systems, and CMC strategies from 2000+ industry experts.
OSI shows you these modalities in action: GLP-1 peptide therapies, siRNA-mediated metabolic targeting, RNA-based obesity approaches, and next-generation multi-agonist treatments transforming patient outcomes.
Expanded Networking Across the Value Chain
Connect with 2,000+ pharmaceutical executives, biotech innovators, clinical researchers, and investors across both events. Build relationships spanning from discovery scientists optimizing oligonucleotide chemistry to commercial leaders navigating market access for obesity therapeutics.
Strategic Advantage for Multiple Stakeholders
For R&D Teams: Understand how oligonucleotide and peptide platforms translate into breakthrough obesity treatments
For Business Development: Identify licensing opportunities and partnership potential across modality development and therapeutic application
For Investors: Evaluate the full value chain from platform technology to commercial viability in one of healthcare's fastest-growing markets
For Clinical Teams: Connect preclinical innovation with clinical trial design and real-world evidence generation
Cross-Pollinate Expertise
Gain dual perspectives on therapeutic innovation:
- Technical depth at TIDES USA: CMC efficiency, formulation strategies, delivery optimization, and manufacturing scale-up
- Clinical and commercial application at OSI: Real-world efficacy data, patient adherence strategies, regulatory approval pathways, and investment trends